Interleukin-1 Receptor Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial∗

Critical Care Medicine

Volumn 44, Issue 2, 2016, Pages 275-281

  Shakoory, Bita ^a   Carcillo, Joseph A ^b   Chatham, W Winn ^c   Amdur, Richard L ^d   Zhao, Huaqing ^d   Dinarello, Charles A ^e   Cron, Randall Q ^f   Opal, Steven M ^g  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c The University of Alabama at Birmingham   (United States)

^d TEMPLE UNIVERSITY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f University of Alabama at Birmingham   (United States)

^g BROWN UNIVERSITY   (United States)

Author keywords

anakinra; disseminated intravascular coagulation; hepatobiliary dysfunction; interleukin 1 receptor antagonist; macrophage activation syndrome; multiorgan dysfunction syndrome; sepsis mortality

Indexed keywords

INTERLEUKIN 1 RECEPTOR; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANONYMISED DATA; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTINUOUS INFUSION; CYTOPENIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; EUROPE; FEMALE; FEVER; HEPATOBILIARY DISEASE; HUMAN; HYPERFERRITINEMIA; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NORTH AMERICA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SHOCK; SURVIVAL; TREATMENT OUTCOME; ACUTE KIDNEY INJURY; ADOLESCENT; AGE; ANTAGONISTS AND INHIBITORS; APACHE; BILIARY TRACT DISEASES; CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR COAGULATION; DOUBLE BLIND PROCEDURE; LIVER DISEASES; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; SEX DIFFERENCE; SHOCK, SEPTIC; VERY ELDERLY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; APACHE; BILIARY TRACT DISEASES; DISSEMINATED INTRAVASCULAR COAGULATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LIVER DISEASES; MACROPHAGE ACTIVATION SYNDROME; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RECEPTORS, INTERLEUKIN-1; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; SEX FACTORS; SHOCK, SEPTIC; YOUNG ADULT;

EID: 84954310841     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001402     Document Type: Article

References (47)

1. Levy MM, Fink MP, Marshall JC, SCCM/ESICM/ACCP/ATS/SIS 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003 31 1250 1256
2. Hotchkiss RS, Karl IE., The pathophysiology and treatment of sepsis. N Engl J
3. Dinarello CA, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011 117 3720 3732
4. Dinarello CA, Renfer L, Wolff SM, Human leukocytic pyrogen: Purification and development of a radioimmunoassay. Proc Natl Acad Sci USA 1977 74 4624 4627
5. Dinarello CA, Rosenwasser LJ, Wolff SM, Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans. J Immunol 1981 127 2517 2519
6. Dinarello CA, Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 1984 311 1413 1418
7. Granowitz EV, Clark BD, Mancilla J, Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991 266 14147 14150
8. Dinarello CA, Simon A, van der Meer JW, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012 11 633 652
9. Granowitz EV, Porat R, Mier JW, Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992 4 353 360
10. Fisher CJ Jr, Slotman GJ, Opal SM, IL-1RA Sepsis Syndrome Study Group Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994 22 12 21
11. Fisher CJ Jr, Dhainaut JF, Opal SM, Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994 271 1836 1843
12. Opal SM, Fisher CJ Jr, Dhainaut JF, Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997 25 1115 1124
13. Schulert GS, Grom AA, Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med 2015 66 145 159
14. Mazodier K, Marin V, Novick D, Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005 106 3483 3489
15. Emmenegger U, Schaer DJ, Larroche C, Haemophagocytic syndromes in adults: Current concepts and challenges ahead. Swiss Med Wkly 2005 135 299 314
16. Cron RQ, Davi S, Minoia F, Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol 2015 11 1043 1053
17. Ravelli A, Grom AA, Behrens EM, Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: Diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012 13 289 298
18. Minoia F, Davì S, Horne A, Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014 66 3160 3169
19. Ravelli A, Magni-Manzoni S, Pistorio A, Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005 146 598 604
20. Fardet L, Galicier L, Lambotte O, Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014 66 2613 2620
21. Rivière S, Galicier L, Coppo P, Reactive hemophagocytic syndrome in adults: A retrospective analysis of 162 patients. Am J Med 2014 127 1118 1125
22. Shabbir M, Lucas J, Lazarchick J, Secondary hemophagocytic syndrome in adults: A case series of 18 patients in a single institution and a review of literature. Hematol Oncol 2011 29 100 106
23. Behrens EM, Beukelman T, Paessler M, Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007 34 1133 1138
24. Bleesing J, Prada A, Siegel DM, The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007 56 965 971
25. Allen CE, Yu X, Kozinetz CA, Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008 50 1227 1235
26. Møller HJ, Moestrup SK, Weis N, Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med 2006 34 2561 2566
27. Schaer DJ, Schleiffenbaum B, Kurrer M, Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 2005 74 6 10
28. Castillo L, Carcillo J, Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 2009 10 387 392
29. Castillo L, High elevated ferritin levels and the diagnosis of HLH/Sepsis/SIRS/MODS/MAS. Pediatr Blood Cancer 2008 51 710; author reply 710 710; author reply 711
30. Hughes CG, Morandi A, Girard TD, Association between endothelial dysfunction and acute brain dysfunction during critical illness. Anesthesiology 2013 118 631 639
31. Strauss R, Neureiter D, Westenburger B, Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients-a postmortem clinicopathologic analysis. Crit Care Med 2004 32 1316 1321
32. Schaer DJ, Schaer CA, Schoedon G, Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. Eur J Haematol 2006 77 432 436
33. Behrens EM, Kreiger PA, Cherian S, Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 2006 33 2081 2084
34. Kelly A, Ramanan AV, A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008 4 615 620
35. Kahn PJ, Cron RQ, Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol 2013 40 743 744
36. Loh NK, Lucas M, Fernandez S, Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Intern Med J 2012 42 1358 1362
37. Durand M, Troyanov Y, Laflamme P, Macrophage activation syndrome treated with anakinra. J Rheumatol 2010 37 879 880
38. Bruck N, Suttorp M, Kabus M, Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011 17 23 27
39. Rajasekaran S, Kruse K, Kovey K, Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children∗. Pediatr Crit Care Med 2014 15 401 408
40. Simon DW, Aneja R, Carcillo JA, Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia-associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis syndrome∗. Pediatr Crit Care Med 2014 15 486 488
41. Tayer-Shifman OE, Ben-Chetrit E., Refractory macrophage activation syndrome in a patient with SLE and APLA syndrome-Successful use of PET-CT and Anakinra in its diagnosis and treatment. Mod Rheumatol 2013 Oct 21. [Epub ahead of print]
42. Shafferman A, Birmingham JD, Cron RQ, High dose anakinra for treatment of severe neonatal Kawasaki disease: A case report. Pediatr Rheumatol Online J 2014 12 26
43. Kumar N, Goyal J, Goel A, Macrophage activation syndrome secondary to human monocytic ehrlichiosis. Indian J Hematol Blood Transfus 2014 30 145 147
44. Miettunen PM, Narendran A, Jayanthan A, Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: Case series with 12 patients. Rheumatology (Oxford) 2011 50 417 419
45. Martí-Carvajal AJ, Solà I, Gluud C, Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev 2012 12 CD004388
46. Mertens M, Singh JA, Anakinra for rheumatoid arthritis: A systematic review. J Rheumatol 2009 36 1118 1125
47. Murray JF, Matthay MA, Luce JM, An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988 138 720 723